Jordanian FDA Drug Director Laila Jarrar On Collaborations With Korean Regulators To Spur Biologics Growth - An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
The fast-growing pharmaceutical market in the Middle East has seen an increasing demand for regulators to step up to new challenges such as biologics and biosimilars, and to answer the call they are enhancing collaborations with leading health authorities around the world.
You may also be interested in...
Saudi FDA Licensing Director Hajed Hashan On CTD And Drug Licensing: An Interview With PharmAsia News
As licensing director of the Saudi Food and Drug Administration, Dr. Hajed Hashan plays a key role in the largest pharmaceutical market in the Gulf region and one of the largest in the Middle East. Established in 2004, SFDA has recently initiated several changes aimed at standardizing its filing and registration process and making SFDA the leading regional health regulator. Along the sidelines of the Drug Information Association's Middle East Regulatory Conference in Amman, Jordan, Hashan spoke to PharmAsia News about some of SFDA's newest initiatives, regulatory challenges and the pharmaceutical environment in the kingdom.
Saudi FDA Licensing Director Hajed Hashan On CTD And Drug Licensing: An Interview With PharmAsia News
As licensing director of the Saudi Food and Drug Administration, Dr. Hajed Hashan plays a key role in the largest pharmaceutical market in the Gulf region and one of the largest in the Middle East. Established in 2004, SFDA has recently initiated several changes aimed at standardizing its filing and registration process and making SFDA the leading regional health regulator. Along the sidelines of the Drug Information Association's Middle East Regulatory Conference in Amman, Jordan, Hashan spoke to PharmAsia News about some of SFDA's newest initiatives, regulatory challenges and the pharmaceutical environment in the kingdom.
Jordanian Drug Maker Buys Baxter Injectable Business, Becomes Second Largest In U.S.
Fast-growing Jordanian drug maker Hikma will acquire Baxter Healthcare's U.S. generic injectables business for $112 million. The acquisition doubles Hikma's injectables business and bolsters the company to the No. 2 position in the U.S. market with a projected market share of more than 15 percent. It also solidifies Hikma's leading position in the Middle East and North African (MENA) market, one of the rapidly growing "pharmerging" markets in the world